|  Help  |  About  |  Contact Us

Publication : Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate bases on a novel recombinant RBD fusion heterodimer of SARS-CoV-2.

First Author  Barreiro A Year  2021
Journal  bioRxiv Mgi Jnum  J:315723
Mgi Id  MGI:6831187 Doi  10.1101/2021.117.22.46911
Citation  Barreiro A, et al. (2021) Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate bases on a novel recombinant RBD fusion heterodimer of SARS-CoV-2. bioRxiv
Paste the following link
Quick Links:
SummaryExpressionOther
 
Quick Links:
SummaryExpressionOther
 
Lists
This Publication isn't in any lists. Upload a list.

Expression

Publication --> Expression annotations

 

Other

5 Authors

5 Bio Entities

Trail: Publication

0 Expression





MouseMine is a collaboration between MGI at The Jackson Laboratory and the InterMine project at the Cambridge Systems Biology Centre. MouseMine is funded through a grant from the NIH/NHGRI.The Jackson Laboratory makes no representation about the suitability or accuracy of this software or data for any purpose, and makes no warranties, either express or implied, including merchantability and fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademarks, or other rights. the software and data are provided "as is". This software and data are provided to enhance knowledge and encourage progress in the scientific community and are to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of the Jackson Laboratory.

Copyright © 2017 by The Jackson Laboratory. All Rights Reserved

© 2002 - 2017 Department of Genetics, University of Cambridge, Downing Street,
Cambridge CB2 3EH, United Kingdom